Kanami Sugimoto‐Kawabata

Statistics

Publications

Citations

H-Index

Active since

2013

Affiliations

Mitsubishi Tanabe Pharma Corporation(Current)

Kanami Sugimoto‐Kawabata is an author at Mitsubishi Tanabe Pharma Corporation specializing in cholesterol-lowering effects, lipid metabolism pathways, and triglyceride metabolism.

Publications per year

2013–2024

Publications

First‐in‐human study evaluating safety, pharmacokinetics, and pharmacodynamics of lorundrostat, a novel and highly selective aldosterone synthase inhibitor

H. Shimizu, Michael A. Tortorici, Yoshiyasu Ohta et al. · Clinical and Translational Science · 2024 · 26 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +16

Colestilan decreases weight gain by enhanced NEFA incorporation in biliary lipids and fecal lipid excretion

Kanami Sugimoto‐Kawabata, Hiroshi Shimada, Kaoru Sakai et al. · Journal of Lipid Research · 2013 · 17 citations · Full text

Life Sciences, Endocrinology, Nutritional Sciences +17

1–2 of 2